Recombinant Human Erythropoietin for the Treatment of Renal Anaemia in Children: No Justification for Bodyweight-Adjusted Dosage

Clinical Pharmacokinetics

Volumn 43, Issue 1, 2004, Pages 57-70

  Port, Ruediger E ^a   Kiepe, Daniela ^b   Van Guilder, Michael ^c   Jelliffe, Roger W ^c   Mehls, Otto ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BODY WEIGHT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RENAL ANEMIA;

ADOLESCENT; ADULT; ANEMIA; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN, RECOMBINANT; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MODELS, BIOLOGICAL; RENAL DIALYSIS; STATISTICS, NONPARAMETRIC;

EID: 0442291791     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200443010-00004     Document Type: Article

References (39)

1. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14 Suppl. 5: 1-50
2. National Kidney Foundation. K/DOQ1 Clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis 2001; 37 Suppl. 1: S182-238
3. Eckardt KU. Erythropoietin: Karriere eines Hormons. Dtsch Arztebl 1998; 95: A-255-90
4. Scigalla P. Effect of recombinant human erythropoietin treatment on renal anemia and body growth of children with end-stage renal disease. In: Baldamus CA, Scigalla P, Wieczorek L, et al, editors. Erythropoietin in renal and non-renal anemias. Basel: Karger, 1991
5. Gagnadoux MF, Loirat C, Bertheleme JP, et al. Treatment of anemia in hemodialyzed children using recombinant human erythropoietin (Eprex). Results of a French multicenter clinical trial [in French]. Nephrologie 1994; 15: 207-11
6. Jabs K, Alexander S, McCabe D. Primary results from the U.S. multicenter pediatric recombinant erythropoietin (epo) study [abstract]. J Am Soc Nephrol 1994; 5: 456
7. van Damme-Lombaerts R, Broyer M, Businger J, et al. A study of recombinant human erythropoietin in the treatment of anemia of chronic renal failure in children on haemodialysis. Pediatr Nephrol 1994; 8: 338-42
8. van Damme-Lombaerts R, Herman J. Erythropoietin treatment in children with renal failure. Pediatr Nephrol 1999; 13: 148-52
9. Uehlinger DE, Gotch FA. A pharmacodynamic model of erythropoietin therapy for uremic anemia [abstract]. J Am Soc Nephrol 1990; 1: 324
10. Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992; 51: 76-89
11. Brockmoeller J, Koechling J, Weber W, et al. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in hemodialysis patients. Br J Clin Pharmacol 1992; 34: 499-508
12. Bellazzi R. Drug delivery optimization through Bayesian networks: an application to erythropoietin therapy in uremic anemia. Comput Biomed Res 1992; 26: 274-93
13. Matzke GR, Comstock T, Frye RF, et al. Computerized Bayesian pharmacodynamic modeling for erythropoietin dosage individualization [abstract]. J Am Soc Nephrol 1994; 5: 464
14. Port RE, Ding RW, Fies T, et al. Predicting the time course of haemoglobin in children treated with erythropoietin for renal anaemia. Br J Clin Pharmacol 1998; 46: 461-6
15. Scigalla P, Bonzel KE, Bulla M, et al. Therapy of renal anemia with recombinant human erythropoietin in children with end-stage renal disease. In: Gurland HL, Moran J, Samtleben W, et al, editors. Erythropoietin: from molecular structure to clinical application. Basel: Karger, 1989
16. Eadie GS, Brown IW. Red blood cell survival studies. Blood 1953; 8: 1110-36
17. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd ed. Baltimore (MD): Williams & Wilkins, 1995
18. Harris JW, Kellermeyer RW. The Red Cell. 2nd ed. Cambridge (MA): Harvard University Press, 1970
19. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol 1992; 32: 185-209
20. Jelliffe R, Schumitzky A, van Guilder M. Population pharmacokinetics/ pharmacodynamics modeling: parametric and nonparametric methods. Ther Drug Monit 2000; 22: 354-65
21. Beal SL, Sheiner LB, editors. NONMEM version V.1.1, user's guides. San Francisco (CA): NONMEM Project Group, University of California, San Francisco, 1999
22. Leary RH, Jelliffe RW, Schumitzky A, et al. Non-parametric pharmacokinetic/dynamic population modeling with adaptive grids [abstract]. Clin Pharmacol Ther 2001; 69: P58
23. MathSoft Inc. S-Plus, version 6.0, release 1 for Linux 2.2.12 or higher. Seattle (WA): MathSoft Inc., 2001
24. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5: 445-79
25. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-12
26. Kling PJ, Widness JA, Guillery EN, et al. Pharmacokinetics and pharmacodynamics of erythropoietin during therapy in an infant with renal failure. J Pediatr 1992; 121: 822-5
27. Widness JA, Veng-Pedersen P, Modi NB, et al. Developmental differences in erythropoietin pharmacokinetics: increased clearance and distribution in fetal and neonatal sheep. J Pharmacol Exp Ther 1992; 261: 977-84
28. Widness JA, Veng-Pedersen P, Peters C, et al. Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects. J Appl Physiol 1996; 80: 140-8
29. Veng-Pedersen P, Widness JA, Pereira LM, et al. A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans. Biopharm Drug Dispos 1999; 20: 217-23
30. Chapel SH, Veng-Pedersen P, Schmidt RL, et al. Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics. Exp Hematol 2001; 29: 425-31
31. Veng-Pedersen P, Widness JA, Pereira LM, et al. Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis, application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans. J Pharm Sci 1995; 84: 760-7
32. Veng-Pedersen P, Widness JA, Wang J, et al. A tracer interaction method for nonlinear pharmacokinetics analysis: application to evaluation of nonlinear elimination. J Pharmacokinet Biopharm 1997; 25: 569-93
33. 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep. J Pharmacol Exp Ther 1996; 279: 1205-10
34. Juul SE. Erythropoietin in the neonate. Curr Probl Pediatr 1999; 29 (5): 133-49
35. Juul SE. Nonerythropoietic roles of erythropoietin in the fetus and neonate. Clin Perinatol 2000; 27: 527-41
36. Bommer J, Barth HP, Zeier M, et al. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol 1991; 88: 136-43
37. Jelliffe RW, Schumitzky A, Bayard D, et al. Model-based, goal-oriented, individualised drug therapy, linkage of population modelling, new 'multiple model' dosage design, Bayesian feedback and individualised target goals. Clin Pharmacokinet 1998; 34: 57-77
38. Steimer JL, Mallet A, Mentre F. Estimating interindividual pharmacokinetic variability. In: Rowland M, Sheiner LB, Steimer JL, editors. Variability in drug therapy. New York: Raven Press, 1985: 65-111
39. Mallet A. A maximum likelihood estimation method for random coefficient regression models. Biometrika 1986; 73: 645-56